Kinase Inhibitor News and Research

RSS
A protein kinase inhibitor is a type of enzyme inhibitor that specifically blocks the action of one or more protein kinases.
Researchers find new target for disease of the heart's smallest blood vessels

Researchers find new target for disease of the heart's smallest blood vessels

New drug combinations and dosing schedules improve outlook in advanced colon cancer

New drug combinations and dosing schedules improve outlook in advanced colon cancer

Study suggests usefulness of more flexible dose of regorafenib to relieve side-effects in mCRC patients

Study suggests usefulness of more flexible dose of regorafenib to relieve side-effects in mCRC patients

Study shows how SIRT1 plays key role in maintaining the regenerative potential of leukemic stem cells

Study shows how SIRT1 plays key role in maintaining the regenerative potential of leukemic stem cells

Still-to-be-approved drug proves to be new option for treating active rheumatoid arthritis

Still-to-be-approved drug proves to be new option for treating active rheumatoid arthritis

Researchers discover unique approach to treat some chronic inflammatory diseases

Researchers discover unique approach to treat some chronic inflammatory diseases

Scientists use a promiscuous inhibitor to uncover cancer drug targets

Scientists use a promiscuous inhibitor to uncover cancer drug targets

FDA extends indication of metastatic breast cancer treatment to include male patients

FDA extends indication of metastatic breast cancer treatment to include male patients

Understanding maintenance of quiescent stem cells in chronic myelogenous leukemia

Understanding maintenance of quiescent stem cells in chronic myelogenous leukemia

New research finds how cancer cells acquire resistance to molecular-targeted drugs

New research finds how cancer cells acquire resistance to molecular-targeted drugs

Researchers discover origin of resistance to lung cancer

Researchers discover origin of resistance to lung cancer

Bio-Rad launches new digital PCR system and kit for monitoring treatment response in CML patients

Bio-Rad launches new digital PCR system and kit for monitoring treatment response in CML patients

Researchers identify promising therapeutic option to treat multiple sclerosis

Researchers identify promising therapeutic option to treat multiple sclerosis

New drug combination could kill melanoma cells more effectively, study shows

New drug combination could kill melanoma cells more effectively, study shows

Triple combination cancer immunotherapy improves survival in mouse model of melanoma

Triple combination cancer immunotherapy improves survival in mouse model of melanoma

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Study offers new hope to patients with rare brain cancer

Study offers new hope to patients with rare brain cancer

Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC

Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC

Study: Erlotinib improves progression-free survival in EGFR mutated NSCLC

Study: Erlotinib improves progression-free survival in EGFR mutated NSCLC

Study: Sarcoma patients poorly informed about risk of interactions with anti-cancer drugs

Study: Sarcoma patients poorly informed about risk of interactions with anti-cancer drugs

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.